AKBA - Akebia Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.05
+0.21 (+1.42%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.84
Open14.87
Bid12.19 x 100
Ask15.86 x 700
Day's Range14.75 - 15.09
52 Week Range8.26 - 20.25
Volume628,739
Avg. Volume365,003
Market Cap711.401M
Beta1.00
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?
    Zacks4 days ago

    Market Has Not Yet Noticed Potential in Akebia Therapeutics (AKBA); Have You?

    Akebia Therapeutics (AKBA) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

  • Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)
    Zacks10 days ago

    Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI)

    Aerie Pharmaceuticals (AERI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
    Zacks11 days ago

    The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

    The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

  • 5 Top-Ranked Drug Stocks that are Broker Favorites
    Zacks12 days ago

    5 Top-Ranked Drug Stocks that are Broker Favorites

    With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

  • Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session
    Zacks13 days ago

    Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session

    Concert Pharmaceuticals (CNCE) saw its shares rise nearly 6% on the day.

  • GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%
    Zacks19 days ago

    GlycoMimetics (GLYC) Jumps: Stock Rises 11.9%

    GlycoMimetics (GLYC) was a big mover last session, as the company saw its shares nearly 10%on the day amid huge volumes.

  • Associated Presslast month

    Akebia Therapeutics reports 3Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 49 cents. The kidney disease treatment developer posted revenue of $41.3 million in the period. Akebia Therapeutics ...

  • Is Akebia Therapeutics Inc’s (AKBA) Liquidity As Good As Its Solvency?
    Simply Wall St.last month

    Is Akebia Therapeutics Inc’s (AKBA) Liquidity As Good As Its Solvency?

    Akebia Therapeutics Inc (NASDAQ:AKBA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is AKBARead More...

  • Capital Cube2 months ago

    Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : October 27, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Akebia Therapeutics, Inc. a score of 29. Our analysis is based on comparing Akebia Therapeutics, Inc. with the following peers – Novartis AG Sponsored ADR, Johnson & Johnson, Nektar Therapeutics, Amgen Inc., Keryx Biopharmaceuticals, Inc. and Enzon Pharmaceuticals, Inc. (NVS-US, JNJ-US, NKTR-US, AMGN-US, KERX-US and ENZN-US). Investment ... Read more (Read more...)

  • Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : October 26, 2017
    Capital Cube2 months ago

    Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : October 26, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Akebia Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • TheStreet.com3 months ago

    Axovant Shares Plummet On Alzheimer's Data; Genocea Gets Rocked -Biotech Movers

    The company said Tuesday its Phase 3 study of intepirdine in patients with Alzheimer's disease did not achieve its co-primary efficacy endpoints.Meanwhile, shares of Genocea Biosciences Inc. were down, ...

  • Ex-Akebia employee suspected of insider trading re-arrested
    Reuters3 months ago

    Ex-Akebia employee suspected of insider trading re-arrested

    A former Akebia Therapeutics Inc (AKBA.O) employee accused of insider trading was re-arrested on Friday after violating a bail condition as a prosecutor who once called him "increasingly unhinged" said he would seek the man's detention pending trial. Schultz Chan, the former director of biostatistics at the Cambridge, Massachusetts-based biopharmaceutical company, had been free on $250,000 bond since his arrest last year on charges brought by federal prosecutors in Boston. While the reason was unclear, Chan's lawyer, Peter Horstmann, cited a condition that Chan report to his probation officer on Tuesday and Fridays.

  • BioMarin Presents Interim Data on BMN 250 from Phase I/II
    Zacks3 months ago

    BioMarin Presents Interim Data on BMN 250 from Phase I/II

    BioMarin's (BMRN) interim data from a current dose escalation phase I/II study on BMN 250 shows improvement signs in cognitive Development Quotient.

  • Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge
    Zacks3 months ago

    Why Akebia Therapeutics (AKBA) Could Be Positioned for a Surge

    Akebia Therapeutics (AKBA), could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

  • Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017
    Capital Cube4 months ago

    Akebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : August 14, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Akebia Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Associated Press4 months ago

    Akebia Therapeutics reports 2Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 53 cents. The kidney disease treatment developer posted revenue of $28.5 million in the period. Akebia Therapeutics ...

  • Capital Cube5 months ago

    ETFs with exposure to Akebia Therapeutics, Inc. : July 24, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Akebia Therapeutics, Inc. Here are 5 ETFs with the largest exposure to AKBA-US. Comparing the performance and risk of Akebia Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Reuters5 months ago

    Ex-Akebia employee faces losing bail in insider trading case

    Schultz Chan, who had been the director of biostatistics at the Cambridge, Massachusetts-based biopharmaceutical company, has been free on $250,000 bond since arrest last year on charges brought by federal prosecutors in Boston. Cabell had ordered the weekly check-ins less than two weeks ago after prosecutors said that Chan's wife had booked airline tickets for herself, Chan and their daughter to fly to China. Frank told the magistrate on Thursday he was increasingly concerned that Chan may be a danger to himself and others, saying he has made threatening comments to his probation officer and the prosecution.

  • Capital Cube5 months ago

    ETFs with exposure to Akebia Therapeutics, Inc. : July 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Akebia Therapeutics, Inc. Here are 5 ETFs with the largest exposure to AKBA-US. Comparing the performance and risk of Akebia Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube5 months ago

    Akebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : July 12, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Akebia Therapeutics, Inc. a score of 29. Our analysis is based on comparing Akebia Therapeutics, Inc. with the following peers – Novartis AG Sponsored ADR, Johnson & Johnson, Nektar Therapeutics, Amgen Inc., Keryx Biopharmaceuticals, Inc. and Enzon Pharmaceuticals, Inc. (NVS-US, JNJ-US, NKTR-US, AMGN-US, KERX-US and ENZN-US). Investment ... Read more (Read more...)

  • Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017
    Capital Cube5 months ago

    Akebia Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : AKBA-US : July 11, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Akebia Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • TheStreet.com6 months ago

    Biotech Movers: Akebia Shares Down After Pricing Stock Offering

    Akebia Therapeutics, Sarepta Therapeutics and Esperion Therapeutics were among the biotech stock movers in premarket trading on June 29.

  • Forbes7 months ago

    Four Stocks Moving On Both News And The Charts

    Here are four stocks moving on both news and strong technicals.

  • Why Akebia Therapeutics Stock Is Skyrocketing Today
    Motley Fool7 months ago

    Why Akebia Therapeutics Stock Is Skyrocketing Today

    Akebia Therapeutics gets a sizable equity investment from Vifor Pharma as part of a supply agreement for the experimental anemia drug vadadustat.

  • TheStreet.com7 months ago

    Biotech Movers: Akebia, Editas, Novavax

    Akebia Therapeutics, Editas Medicine and Novavax were among the biotech movers in premarket trading on Tuesday.